Highlight
1. Injectable GLP-1 receptor agonist use among US adults with diabetes rose sharply from 4% in 2016 to nearly 27% in 2024.
2. Hispanic adults with diabetes had the highest usage rates (~31%) compared to other ethnic groups.
3. Usage was more prevalent in adults with overweight or obesity and in middle-aged groups (50-64 years).
4. No significant differences in injectable GLP-1 use were observed based on sex or family income.
